Write in a clean editor, then format for NDT Plus in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
NDT Plus is a peer-reviewed journal published by Oxford University Press, covering Dialysis and Renal Disease Management, Diabetes Treatment and Management, Erythropoietin and Anemia Treatment.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', NDT Plus, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — NDT Plus has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Dialysis and Renal Disease Management Diabetes Treatment and Management Erythropoietin and Anemia Treatment Diverse Scientific and Economic Studies Heart Failure Treatment and Management |
| ISSN | 1753-0784 |
| h-index | 4 |
| i10-index | 3 |
| Total citations | 352 |
| Top institutions publishing here | Marqués de Valdecilla University Hospital |
| Journal website | ndtplus.oxfordjournals.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire. Thus the market is opening for generic versions, referred to as 'biosimilars' (European Union) or 'follow-on protein products' (United States). Healthcare professionals need to understand the critical issues surrounding the use of biosimilars to make informed treatment decisions.The complex…
The availability of erythropoiesis-stimulating agents (ESAs) has revolutionized the treatment of anaemia in patients with chronic kidney disease. However, maintaining patients at haemoglobin (Hb) levels that are both safe and provide maximal benefit is a continuing challenge in the field. Based on emerging data on the potential risks of Hb treatment targets >13 g/dL, treatment…
The introduction of erythropoiesis-stimulating agents (ESAs) into everyday clinical practice has greatly improved the care of patients with chronic kidney disease. ESAs have reduced the need for blood transfusions, improved survival, decreased cardiovascular complications and enhanced patient quality of life. The longer acting ESA, darbepoetin alfa (Aranesp(R)), which can be administered less frequently than traditional…
The introduction of erythropoiesis-stimulating agents (ESAs) revolutionized the management of anaemia in chronic kidney disease (CKD) patients by providing effective control of haemoglobin (Hb) levels, reducing the need for blood transfusions and improving patient quality of life. The use of ESAs in CKD patients is constantly evolving as new research helps us to better understand…
Patients with chronic kidney disease (CKD) have a high burden of mortality and cardiovascular morbidity. Additional strategies to modulate cardiovascular risk in this population are needed. Anaemia has been associated with adverse outcomes in CKD populations, and the ability to modify this parameter with the use of erythropoiesis-stimulating agents has been a topic of much…
